Creative Planning
SLDB icon

Creative Planning’s Solid Biosciences SLDB Stock Holding History

Creative Planning’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$358K Buy
35,860
+1,294
+4% +$9.81K ﹤0.01% 3431
2026
Q1 		$249K Buy
34,566
+9,677
+39% +$62.2K ﹤0.01% 3572
2025
Q4 		$140K Buy
24,889
+8,574
+53% +$46.5K ﹤0.01% 3648
2025
Q3 		$101K Buy
16,315
+4,514
+38% +$26.4K ﹤0.01% 3668
2025
Q2 		$57.5K Buy
+11,801
New +$41.7K ﹤0.01% 3505
2021
Q1 		– Sell
-1,000
Closed -$114K – 2708
2020
Q4 		$114K Buy
+1,000
New +$63.2K ﹤0.01% 2011

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Creative Planning's SLDB Position: Q2 2026 in Review

Creative Planning increased its Solid Biosciences (SLDB) stake by 3.7% in Q2 2026, buying an estimated $9.81K and bringing the position to 35,860 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #3431.

Creative Planning first reported a position in SLDB in Q4 2020 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Creative Planning held 35,860 shares of Solid Biosciences worth $358K as of Q2 2026.
  • Creative Planning bought 1,294 Solid Biosciences shares in Q2 2026, an estimated $9.81K.
  • Solid Biosciences made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3431 holding.
  • Creative Planning first reported a position in Solid Biosciences in Q4 2020 and has held it in 6 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.